Evidence map›Paper›PMID 40759225›Full record

ArticleInternational journal of pharmaceutics2025

Novel oral LAAM immediate-release capsules for treating opioid use disorder.

Zixuan Zhen, Hadi Sudarjat, Katherine Pierce, Jonathan Hu, Yuying Pan, Chaolong Qin, Diane Ingabire, Long Zhao, Adam Pearcy, F Gerard Moeller and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zixuan ZhenSchool of Pharmacy, Department of Pharmaceutical Sciences, University of Connecticut, 06269, USA.
Hadi SudarjatSchool of Pharmacy, Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Katherine PierceSchool of Pharmacy, Department of Pharmaceutical Sciences, University of Connecticut, 06269, USA.
Jonathan HuSchool of Pharmacy, Department of Pharmaceutical Sciences, University of Connecticut, 06269, USA.
Yuying PanCollege of Liberal Art and Sciences, Department of Statistics, University of Connecticut, USA.
Chaolong QinSchool of Pharmacy, Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Diane IngabireSchool of Medicine, Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Long ZhaoSchool of Pharmacy, Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Adam PearcySchool of Pharmacy, Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
F Gerard MoellerSchool of Medicine, Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Charles O'KeeffeSchool of Medicine, Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Matthew S HalquistSchool of Pharmacy, Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA.
Qingguo XuSchool of Pharmacy, Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298, USA; Center for Pharmaceutical Engineering, Center for Drug Discovery, Department of Pediatrics, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA. Electronic address: qxu@vcu.edu.
Xiuling LuSchool of Pharmacy, Department of Pharmaceutical Sciences, University of Connecticut, 06269, USA. Electronic address: xiuling.lu@uconn.edu.

Funding

TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
Novel LAAM formulations to treat Opioid Use Disorder (UG3 DA048768-01A1)UG3DA048768 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HALQUIST, MATTHEW SEAN, MOELLER, FREDERICK GERARD · 2019 to 2019
$1.6M
NIDA NIH HHS T32 DA007027NIDA NIH HHS UG3 DA048768
6 · The paper itself

Abstract

Levo-alpha-acetylmethadol (LAAM) has a long duration of action offering numerous behavioral and clinical advantages for treating opioid use disorders. In this study, we aim to develop a novel oral immediate-release capsule of LAAM, as an alternative to methadone, the major medication that requires daily visits. LAAM solid dispersion-coated pellets were developed with VIVAPUR® MCC Spheres 700 as the core, and LAAM-carrier coating solution was sprayed onto the core pellets using a fluid bed coater. The coating solution formulation was optimized for reduced coating time and improved drug loading efficiency. Design of Experiments (DoE) studies were conducted, revealing the impact of critical process parameters-nozzle air pressure and airflow-on the critical quality attributes of the LAAM-coated pellets. Capsules with different dosage strengths were prepared. Capsule weight variation, content uniformity, and in vitro release tests were conducted based on USP guidelines for quality assessment. The LAAM capsules showed the immediate release profile. The storage stability of the LAAM capsules was evaluated under accelerated condition and room temperature for 6 months. The weight gain, drug content, and dissolution profile were evaluated. The results showed that drug contents and immediate-release properties remained after 6 months of storage. Pharmacokinetic (PK) study in rabbits showed that capsules have longer t

Indexed as

Analgesics, OpioidOpioid-Related DisordersAdministration, OralAnimalsCapsulesChemistry, PharmaceuticalDrug CompoundingDrug LiberationDrug StabilityMaleRabbitsSolubilityAnalgesics, OpioidCapsulesFluid-bed coatingLevo-alpha-acetylmethadolOpioid use disordersPharmacokineticsStability tests

Identifiers

PMID40759225
PMCPMC12404046

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.